Typhoid Vaccines Ready for Implementation
Open Access
- 23 July 2009
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 361 (4), 403-405
- https://doi.org/10.1056/nejme0905519
Abstract
Enteric fevers encompass typhoid fever caused by Salmonella enterica serotype Typhi (S. Typhi) and paratyphoid fever caused by serotype Paratyphi A or B (S. Paratyphi). These human-restricted pathogens are acquired by ingesting contaminated water or food, and in the individual patient, one cannot differentiate clinically which agent is causing illness. S. Typhi expresses a capsular “Vi” (for virulence) polysaccharide, whereas S. Paratyphi A and B cannot synthesize Vi.Keywords
This publication has 11 references indexed in Scilit:
- A Cluster-Randomized Effectiveness Trial of Vi Typhoid Vaccine in IndiaNew England Journal of Medicine, 2009
- Ty21a Live Oral Typhoid Vaccine and Prevention of Paratyphoid Fever Caused by Salmonella enterica Serovar Paratyphi BClinical Infectious Diseases, 2007
- The Use of Typhoid Vaccines in Asia: The DOMI ExperienceClinical Infectious Diseases, 2007
- Bacteremic Typhoid Fever in Children in an Urban Slum, BangladeshEmerging Infectious Diseases, 2005
- Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccineVaccine, 1999
- Typhoid fever in children aged less than 5 yearsThe Lancet, 1999
- Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunizationVaccine, 1996
- Oral immunisation against typhoid fever in Indonesia with Ty21a vaccineThe Lancet, 1991
- Comparative Efficacy of Two, Three, or Four Doses of TY21a Live Oral Typhoid Vaccine in Enteric-Coated Capsules: A Field Trial in an Endemic AreaThe Journal of Infectious Diseases, 1989
- Prevention of Typhoid Fever in Nepal with the VI Capsular Polysaccharide ofSalmonella TyphiNew England Journal of Medicine, 1987